Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction
Research output: Contribution to journal › Journal article › Research › peer-review
Longterm survival after curative resection for adenocarcinoma at the gastro-esophageal junction (GEJ) range between 18% and 50%. In the pivotal Intergroup-0116 Phase III trial by Macdonald et all, adjuvant chemoradiotherapy improved both disease-free and overall survival in curatively resected patients with mainly gastric adenocarcinoma. We compared survival data for curatively resected patients with adeno-carcinoma solely at the gastro-esophageal junction (GEJ), treated with surgery alone or surgery and adjuvant chemoradio-therapy.
Original language | English |
---|---|
Journal | Scandinavian Journal of Surgery |
Volume | 101 |
Issue number | 1 |
Pages (from-to) | 26-31 |
Number of pages | 6 |
ISSN | 1457-4969 |
Publication status | Published - 2012 |
ID: 48421312